COVID-19 Impact on Global Recurrent Glioblastoma Multiforme Treatment Market Size, Status and Forecast 2020-2026

September 2020 | 133 pages | ID: CCFF2C372B6CEN
QYResearch

Abstracts

This report focuses on the global Recurrent Glioblastoma Multiforme Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Recurrent Glioblastoma Multiforme Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Boehringer Ingelheim GmbH
• Boston Biomedical, Inc.
• Bristol-Myers Squibb Company
• Cantex Pharmaceuticals, Inc.
• Cavion LLC
• Celldex Therapeutics, Inc.
• Coherus BioSciences, Inc.
• Cortice Biosciences, Inc.
• Eisai
• Eli Lilly and Company
• EnGeneIC Ltd
• ERC Belgium SA
• GenSpera, Inc.
• Genzyme Corporation
• GW Pharmaceuticals Plc
• ImmunoCellular Therapeutics, Ltd.

Market segment by Type, the product can be split into

• AU-105
• Axitinib
• AXL-1717
• AZD-7451
• Others

Market segment by Application, split into

• Hospital
• Clinic
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Recurrent Glioblastoma Multiforme Treatment status, future forecast, growth opportunity, key market and key players.
• To present the Recurrent Glioblastoma Multiforme Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Recurrent Glioblastoma Multiforme Treatment are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme Treatment Revenue
1.4 Market Analysis by Type
  1.4.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 AU-105
  1.4.3 Axitinib
  1.4.4 AXL-1717
  1.4.5 AZD-7451
  1.4.6 Others
1.5 Market by Application
  1.5.1 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application: 2020 VS 2026
  1.5.2 Hospital
  1.5.3 Clinic
  1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Recurrent Glioblastoma Multiforme Treatment Industry Impact
  1.6.1 How the Covid-19 is Affecting the Recurrent Glioblastoma Multiforme Treatment Industry
    1.6.1.1 Recurrent Glioblastoma Multiforme Treatment Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Recurrent Glioblastoma Multiforme Treatment Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Recurrent Glioblastoma Multiforme Treatment Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Recurrent Glioblastoma Multiforme Treatment Market Perspective (2015-2026)
2.2 Recurrent Glioblastoma Multiforme Treatment Growth Trends by Regions
  2.2.1 Recurrent Glioblastoma Multiforme Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Recurrent Glioblastoma Multiforme Treatment Historic Market Share by Regions (2015-2020)
  2.2.3 Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Recurrent Glioblastoma Multiforme Treatment Market Growth Strategy
  2.3.6 Primary Interviews with Key Recurrent Glioblastoma Multiforme Treatment Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Market Size
  3.1.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Revenue (2015-2020)
  3.1.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Players (2015-2020)
  3.1.3 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio
  3.2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme Treatment Revenue in 2019
3.3 Recurrent Glioblastoma Multiforme Treatment Key Players Head office and Area Served
3.4 Key Players Recurrent Glioblastoma Multiforme Treatment Product Solution and Service
3.5 Date of Enter into Recurrent Glioblastoma Multiforme Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Type (2015-2020)
4.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2021-2026)

5 RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)
5.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
6.2 Recurrent Glioblastoma Multiforme Treatment Key Players in North America (2019-2020)
6.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
6.4 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
7.2 Recurrent Glioblastoma Multiforme Treatment Key Players in Europe (2019-2020)
7.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
7.4 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

8 CHINA

8.1 China Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
8.2 Recurrent Glioblastoma Multiforme Treatment Key Players in China (2019-2020)
8.3 China Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
8.4 China Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
9.2 Recurrent Glioblastoma Multiforme Treatment Key Players in Japan (2019-2020)
9.3 Japan Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
9.4 Japan Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
10.2 Recurrent Glioblastoma Multiforme Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

11 INDIA

11.1 India Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
11.2 Recurrent Glioblastoma Multiforme Treatment Key Players in India (2019-2020)
11.3 India Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
11.4 India Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
12.2 Recurrent Glioblastoma Multiforme Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
12.4 Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Boehringer Ingelheim GmbH
  13.1.1 Boehringer Ingelheim GmbH Company Details
  13.1.2 Boehringer Ingelheim GmbH Business Overview and Its Total Revenue
  13.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Introduction
  13.1.4 Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020))
  13.1.5 Boehringer Ingelheim GmbH Recent Development
13.2 Boston Biomedical, Inc.
  13.2.1 Boston Biomedical, Inc. Company Details
  13.2.2 Boston Biomedical, Inc. Business Overview and Its Total Revenue
  13.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
  13.2.4 Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  13.2.5 Boston Biomedical, Inc. Recent Development
13.3 Bristol-Myers Squibb Company
  13.3.1 Bristol-Myers Squibb Company Company Details
  13.3.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
  13.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Introduction
  13.3.4 Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  13.3.5 Bristol-Myers Squibb Company Recent Development
13.4 Cantex Pharmaceuticals, Inc.
  13.4.1 Cantex Pharmaceuticals, Inc. Company Details
  13.4.2 Cantex Pharmaceuticals, Inc. Business Overview and Its Total Revenue
  13.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
  13.4.4 Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  13.4.5 Cantex Pharmaceuticals, Inc. Recent Development
13.5 Cavion LLC
  13.5.1 Cavion LLC Company Details
  13.5.2 Cavion LLC Business Overview and Its Total Revenue
  13.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Introduction
  13.5.4 Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  13.5.5 Cavion LLC Recent Development
13.6 Celldex Therapeutics, Inc.
  13.6.1 Celldex Therapeutics, Inc. Company Details
  13.6.2 Celldex Therapeutics, Inc. Business Overview and Its Total Revenue
  13.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
  13.6.4 Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  13.6.5 Celldex Therapeutics, Inc. Recent Development
13.7 Coherus BioSciences, Inc.
  13.7.1 Coherus BioSciences, Inc. Company Details
  13.7.2 Coherus BioSciences, Inc. Business Overview and Its Total Revenue
  13.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
  13.7.4 Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  13.7.5 Coherus BioSciences, Inc. Recent Development
13.8 Cortice Biosciences, Inc.
  13.8.1 Cortice Biosciences, Inc. Company Details
  13.8.2 Cortice Biosciences, Inc. Business Overview and Its Total Revenue
  13.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
  13.8.4 Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  13.8.5 Cortice Biosciences, Inc. Recent Development
13.9 Eisai
  13.9.1 Eisai Company Details
  13.9.2 Eisai Business Overview and Its Total Revenue
  13.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Introduction
  13.9.4 Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  13.9.5 Eisai Recent Development
13.10 Eli Lilly and Company
  13.10.1 Eli Lilly and Company Company Details
  13.10.2 Eli Lilly and Company Business Overview and Its Total Revenue
  13.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Introduction
  13.10.4 Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  13.10.5 Eli Lilly and Company Recent Development
13.11 EnGeneIC Ltd
  10.11.1 EnGeneIC Ltd Company Details
  10.11.2 EnGeneIC Ltd Business Overview and Its Total Revenue
  10.11.3 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Introduction
  10.11.4 EnGeneIC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  10.11.5 EnGeneIC Ltd Recent Development
13.12 ERC Belgium SA
  10.12.1 ERC Belgium SA Company Details
  10.12.2 ERC Belgium SA Business Overview and Its Total Revenue
  10.12.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Introduction
  10.12.4 ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  10.12.5 ERC Belgium SA Recent Development
13.13 GenSpera, Inc.
  10.13.1 GenSpera, Inc. Company Details
  10.13.2 GenSpera, Inc. Business Overview and Its Total Revenue
  10.13.3 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
  10.13.4 GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  10.13.5 GenSpera, Inc. Recent Development
13.14 Genzyme Corporation
  10.14.1 Genzyme Corporation Company Details
  10.14.2 Genzyme Corporation Business Overview and Its Total Revenue
  10.14.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Introduction
  10.14.4 Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  10.14.5 Genzyme Corporation Recent Development
13.15 GW Pharmaceuticals Plc
  10.15.1 GW Pharmaceuticals Plc Company Details
  10.15.2 GW Pharmaceuticals Plc Business Overview and Its Total Revenue
  10.15.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Introduction
  10.15.4 GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  10.15.5 GW Pharmaceuticals Plc Recent Development
13.16 ImmunoCellular Therapeutics, Ltd.
  10.16.1 ImmunoCellular Therapeutics, Ltd. Company Details
  10.16.2 ImmunoCellular Therapeutics, Ltd. Business Overview and Its Total Revenue
  10.16.3 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Introduction
  10.16.4 ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  10.16.5 ImmunoCellular Therapeutics, Ltd. Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Recurrent Glioblastoma Multiforme Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Recurrent Glioblastoma Multiforme Treatment Revenue
Table 3. Ranking of Global Top Recurrent Glioblastoma Multiforme Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of AU-105
Table 6. Key Players of Axitinib
Table 7. Key Players of AXL-1717
Table 8. Key Players of AZD-7451
Table 9. Key Players of Others
Table 10. COVID-19 Impact Global Market: (Four Recurrent Glioblastoma Multiforme Treatment Market Size Forecast Scenarios)
Table 11. Opportunities and Trends for Recurrent Glioblastoma Multiforme Treatment Players in the COVID-19 Landscape
Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 13. Key Regions/Countries Measures against Covid-19 Impact
Table 14. Proposal for Recurrent Glioblastoma Multiforme Treatment Players to Combat Covid-19 Impact
Table 15. Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions (2015-2020)
Table 19. Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Recurrent Glioblastoma Multiforme Treatment Market Growth Strategy
Table 25. Main Points Interviewed from Key Recurrent Glioblastoma Multiforme Treatment Players
Table 26. Global Recurrent Glioblastoma Multiforme Treatment Revenue by Players (2015-2020) (Million US$)
Table 27. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Players (2015-2020)
Table 28. Global Top Recurrent Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme Treatment as of 2019)
Table 29. Global Recurrent Glioblastoma Multiforme Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Recurrent Glioblastoma Multiforme Treatment Product Solution and Service
Table 32. Date of Enter into Recurrent Glioblastoma Multiforme Treatment Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US$)
Table 35. Global Recurrent Glioblastoma Multiforme Treatment Market Size Share by Type (2015-2020)
Table 36. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2021-2026)
Table 37. Global Recurrent Glioblastoma Multiforme Treatment Market Size Share by Application (2015-2020)
Table 38. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US$)
Table 39. Global Recurrent Glioblastoma Multiforme Treatment Market Size Share by Application (2021-2026)
Table 40. North America Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)
Table 42. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US$)
Table 43. North America Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)
Table 44. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US$)
Table 45. North America Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)
Table 46. Europe Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)
Table 48. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)
Table 50. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)
Table 52. China Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US$)
Table 53. China Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)
Table 54. China Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US$)
Table 55. China Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)
Table 56. China Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US$)
Table 57. China Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)
Table 58. Japan Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)
Table 60. Japan Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)
Table 62. Japan Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)
Table 66. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)
Table 68. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)
Table 70. India Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US$)
Table 71. India Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)
Table 72. India Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US$)
Table 73. India Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)
Table 74. India Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US$)
Table 75. India Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)
Table 78. Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)
Table 80. Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)
Table 82. Boehringer Ingelheim GmbH Company Details
Table 83. Boehringer Ingelheim GmbH Business Overview
Table 84. Boehringer Ingelheim GmbH Product
Table 85. Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 86. Boehringer Ingelheim GmbH Recent Development
Table 87. Boston Biomedical, Inc. Company Details
Table 88. Boston Biomedical, Inc. Business Overview
Table 89. Boston Biomedical, Inc. Product
Table 90. Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 91. Boston Biomedical, Inc. Recent Development
Table 92. Bristol-Myers Squibb Company Company Details
Table 93. Bristol-Myers Squibb Company Business Overview
Table 94. Bristol-Myers Squibb Company Product
Table 95. Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 96. Bristol-Myers Squibb Company Recent Development
Table 97. Cantex Pharmaceuticals, Inc. Company Details
Table 98. Cantex Pharmaceuticals, Inc. Business Overview
Table 99. Cantex Pharmaceuticals, Inc. Product
Table 100. Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 101. Cantex Pharmaceuticals, Inc. Recent Development
Table 102. Cavion LLC Company Details
Table 103. Cavion LLC Business Overview
Table 104. Cavion LLC Product
Table 105. Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 106. Cavion LLC Recent Development
Table 107. Celldex Therapeutics, Inc. Company Details
Table 108. Celldex Therapeutics, Inc. Business Overview
Table 109. Celldex Therapeutics, Inc. Product
Table 110. Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 111. Celldex Therapeutics, Inc. Recent Development
Table 112. Coherus BioSciences, Inc. Company Details
Table 113. Coherus BioSciences, Inc. Business Overview
Table 114. Coherus BioSciences, Inc. Product
Table 115. Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 116. Coherus BioSciences, Inc. Recent Development
Table 117. Cortice Biosciences, Inc. Business Overview
Table 118. Cortice Biosciences, Inc. Product
Table 119. Cortice Biosciences, Inc. Company Details
Table 120. Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 121. Cortice Biosciences, Inc. Recent Development
Table 122. Eisai Company Details
Table 123. Eisai Business Overview
Table 124. Eisai Product
Table 125. Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 126. Eisai Recent Development
Table 127. Eli Lilly and Company Company Details
Table 128. Eli Lilly and Company Business Overview
Table 129. Eli Lilly and Company Product
Table 130. Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 131. Eli Lilly and Company Recent Development
Table 132. EnGeneIC Ltd Company Details
Table 133. EnGeneIC Ltd Business Overview
Table 134. EnGeneIC Ltd Product
Table 135. EnGeneIC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 136. EnGeneIC Ltd Recent Development
Table 137. ERC Belgium SA Company Details
Table 138. ERC Belgium SA Business Overview
Table 139. ERC Belgium SA Product
Table 140. ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 141. ERC Belgium SA Recent Development
Table 142. GenSpera, Inc. Company Details
Table 143. GenSpera, Inc. Business Overview
Table 144. GenSpera, Inc. Product
Table 145. GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 146. GenSpera, Inc. Recent Development
Table 147. Genzyme Corporation Company Details
Table 148. Genzyme Corporation Business Overview
Table 149. Genzyme Corporation Product
Table 150. Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 151. Genzyme Corporation Recent Development
Table 152. GW Pharmaceuticals Plc Company Details
Table 153. GW Pharmaceuticals Plc Business Overview
Table 154. GW Pharmaceuticals Plc Product
Table 155. GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 156. GW Pharmaceuticals Plc Recent Development
Table 157. ImmunoCellular Therapeutics, Ltd. Company Details
Table 158. ImmunoCellular Therapeutics, Ltd. Business Overview
Table 159. ImmunoCellular Therapeutics, Ltd. Product
Table 160. ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US$)
Table 161. ImmunoCellular Therapeutics, Ltd. Recent Development
Table 162. Research Programs/Design for This Report
Table 163. Key Data Information from Secondary Sources
Table 164. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Type: 2020 VS 2026
Figure 2. AU-105 Features
Figure 3. Axitinib Features
Figure 4. AXL-1717 Features
Figure 5. AZD-7451 Features
Figure 6. Others Features
Figure 7. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application: 2020 VS 2026
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Recurrent Glioblastoma Multiforme Treatment Report Years Considered
Figure 12. Global Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions: 2020 VS 2026
Figure 14. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Players in 2019
Figure 17. Global Top Recurrent Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Recurrent Glioblastoma Multiforme Treatment Revenue in 2019
Figure 19. North America Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Boehringer Ingelheim GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Boehringer Ingelheim GmbH Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 28. Boston Biomedical, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Boston Biomedical, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 30. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Bristol-Myers Squibb Company Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 32. Cantex Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Cantex Pharmaceuticals, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 34. Cavion LLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Cavion LLC Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 36. Celldex Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Celldex Therapeutics, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 38. Coherus BioSciences, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Coherus BioSciences, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 40. Cortice Biosciences, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Cortice Biosciences, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 42. Eisai Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Eisai Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 44. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Eli Lilly and Company Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 46. EnGeneIC Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. EnGeneIC Ltd Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 48. ERC Belgium SA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. ERC Belgium SA Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 50. GenSpera, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. GenSpera, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 52. Genzyme Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Genzyme Corporation Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 54. GW Pharmaceuticals Plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. GW Pharmaceuticals Plc Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 56. ImmunoCellular Therapeutics, Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. ImmunoCellular Therapeutics, Ltd. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed